Larkspur Health Acquisition filed an S-4 outlining its proposed merger with ZyVersa Therapeutics, a clinical stage specialty biopharmaceutical company developing medicines to treat renal and inflammatory diseases.
Announced last month, the deal has an enterprise value of $108.9 million.
Terms call for cash proceeds of approximately $77.67 million in Larkspur’s trust account (less any redemptions and expenses) and a $7 million PIPE anchored by new and as-yet unnamed institutional investors.
If approved by the SPAC’s shareholders, the deal is expected to close in the fourth quarter. Shares would list on the Nasdaq under ticker symbol ZVSA. Read more.
